The regulation of immune checkpoint is a pivotal mechanism mediating both self-tolerance physiologically and tumor immune evasion pathologically. Along with an increasing number of identified checkpoint ligand–receptor pairs, the complexity of regulation at genetic, epigenetic, transcriptional, translational, and post-translational levels makes it highly challenging to assemble a comprehensive regulatory network. Advanced animal models are required for determining the exact regulatory effects, given the differences in human and mouse immune systems. Our further understanding on checkpoint regulation may energize translational studies aimed to improve cancer immunotherapy, and collaborations between researchers with different expertise would help to tackle existing challenges in this field.
Immune checkpoint regulation Trans-omics Translational medicine Precision medicine Combinatorial therapy
This is a preview of subscription content, log in to check access.
Conway JR et al (2018) Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine. Genome Med 10(1):93CrossRefGoogle Scholar
Dominguez-Andres J, Netea MG (2019) Impact of historic migrations and evolutionary processes on human immunity. Trends Immunol 40(12):1105–1119CrossRefGoogle Scholar
Strauss J et al (2018) Phase I trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGFbeta. Advanced Solid Tumors. Clin Cancer Res 24(6):1287–1295CrossRefGoogle Scholar
Wang Y et al (2018) Regulation of PD-L1: emerging routes for targeting tumor immune evasion. Front Pharmacol 9:536CrossRefGoogle Scholar